The market dynamics for Aicardi Goutières Syndrome (AGS) are evolving steadily due to increasing awareness of rare genetic interferonopathies, improvements in genetic diagnostic capabilities, and growing research activities focused on targeted immunomodulatory therapies. Additionally, the development of emerging therapies such … Continue reading →

The Interstitial Cystitis market is experiencing steady growth driven by increasing disease awareness, improving diagnosis rates, growing adoption of multimodal treatment strategies, and the development of novel targeted therapies. The emergence of pipeline candidates such as ALENURA (Vaneltix Pharma/Hyloris Pharma), … Continue reading →

The market dynamics for Treatment-Resistant Depression (TRD) are expected to grow significantly due to the rising prevalence of depression, increasing cases unresponsive to standard antidepressants, greater mental health awareness, and advancements in psychedelic-based therapies. Emerging therapies such as COMP360, BPL-003, … Continue reading →

The market dynamics for Essential Thrombocythemia are anticipated to witness notable growth driven by the increasing prevalence of ET, growing awareness regarding myeloproliferative neoplasms, advancements in genetic mutation testing, and increasing focus on preventing thrombotic complications. Additionally, the development of … Continue reading →

The market dynamics for Xerostomia are anticipated to witness notable growth driven by the increasing prevalence of xerostomia associated with aging populations, rising polypharmacy use, increasing cases of Sjögren’s syndrome, growing head and neck cancer survivorship, and improved awareness regarding … Continue reading →

The market dynamics for Basal Cell Carcinoma (BCC) are anticipated to witness notable growth driven by the increasing incidence of BCC, heightened UV exposure, aging population, growing awareness regarding early diagnosis, and the launch of emerging therapies. Additionally, the development … Continue reading →